Browsing by Author "Ross, Patricio"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience
    (2021) Ceballos, Maria Elena; Ross, Patricio; Lasso, Martin; Dominguez, Isabel; Puente, Marcela; Valenzuela, Pablo; Enberg, Margarita; Serri, Michel; Muñoz, Rodrigo; Pinos, Yazmin; Silva, Macarena; Noguera, Matías; Domínguez, Angélica; Zamora, Francisco; Chilean HIV/COVID-19 Study Group
    In this prospective, multicentric, observational study, we describe the clinical characteristics and outcomes of people living with HIV (PLHIV) requiring hospitalization due to COVID-19 in Chile and compare them with Chilean general population admitted with SARS-CoV-2. Consecutive PLHIV admitted with COVID-19 in 23 hospitals, between 16 April and 23 June 2020, were included. Data of a temporally matched-hospitalized general population were used to compare demography, comorbidities, COVID-19 symptoms, and major outcomes. In total, 36 PLHIV subjects were enrolled; 92% were male and mean age was 44 years. Most patients (83%) were on antiretroviral therapy; mean CD4 count was 557 cells/mm3. Suppressed HIV viremia was found in 68% and 56% had, at least, one comorbidity. Severe COVID-19 occurred in 44.4%, intensive care was required in 22.2%, and five patients died (13.9%). No differences were seen between recovered and deceased patients in CD4 count, HIV viral load, or time since HIV diagnosis. Hypertension and cardiovascular disease were associated with a higher risk of death ( p = 0.02 and 0.006, respectively). Compared with general population, the HIV cohort had significantly more men (OR 0.15; IC 95% 0.07–0.31) and younger age (OR 8.68; IC 95% 2.66–28.31). In PLHIV, we found more intensive care unit admission (OR 2.31; IC 95% 1.05–5.07) but no differences in the need for mechanical ventilation or death. In this cohort of PLHIV hospitalized with COVID-19, hypertension and cardiovascular comorbidities, but not current HIV viro-immunologic status, were the most important risk factors for mortality. No differences were found between PLHIV and general population in the need for mechanical ventilation and death.
  • No Thumbnail Available
    Item
    Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
    (2023) Mondaca Contreras, Sebastián Patricio; Walbaum, Benjamín; Corre, Nicole Le; Ferrés Garrido, Marcela Viviana; Valdés, Alejandro; Martínez-Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Macanas Pirard, Patricia; Ross, Patricio; Cisternas, Betzabé; Pérez, Patricia; Cabrera, Olivia; Cerda, Valentina; Ormazábal, Ivana; Barrera Vásquez, Aldo Vincen; Prado, María E.; Venegas, María I.; Palma, Silvia; Broekhuizen, Richard; Kalergis, Alexis; Bueno, Susan M.; Espinoza, Manuel A.; Balcells Marty, María Elvira; Nervi Nattero, Bruno
    Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.